Overview

A 6 Month Study to Compare the Metabolic Effects of Paliperidone ER and Olanzapine in Patients With Schizophrenia

Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this 6 month study is to compare the metabolic effects of paliperidone ER and olanzapine in patients with schizophrenia, using the ratio of the concentration of lipids (triglycerides (TG)) in the blood to the concentration of good cholesterol (high density lipoproteins (HDL)) in the blood as the primary parameter. Approximately 456 adult patients will participate in this study.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen-Cilag International NV
Treatments:
Olanzapine
Paliperidone Palmitate